WOBURN, Mass. — November 24, 2025 — Leads & Copy — Vertero Therapeutics has begun a Phase 1 study of its lead candidate, VT-5006, for the treatment of Parkinson’s disease (PD).
VT-5006, a novel, oral therapeutic developed by Vertero, targets CsgA, a microbial amyloid in the GI wall that drives aggregation of alpha-synuclein (⍺Syn) and inflammation. The drug aims to reduce aggregation and dampen inflammation, potentially alleviating symptoms and slowing disease progression.
Becca Senter, Ph.D., Chief Scientific Officer, said the program reflects the company’s strategy to change the way it approaches neurodegenerative diseases by targeting causative triggers in peripheral systems that fuel these diseases. Senter added that Vertero believes VT-5006 could effectively intervene upstream in the peripheral system to delay onset, slow progression and preserve quality of life for people with Parkinson’s disease, and the company looks forward to the insights this study will generate to support its program.
The Phase 1a portion of the study is enrolling healthy volunteers to receive VT-5006 either as a single dose or once daily for seven days. The primary endpoints include safety, tolerability and pharmacokinetics of VT-5006 at sequentially-ascending doses compared to placebo.
The Phase 1b portion will include adults diagnosed with Parkinson’s disease in the last 10 years, who are at early or moderate stage of disease (Hoehn and Yahr (H&Y) scale < 3), and who are CsgA-positive. Preclinical studies demonstrated reduced pathology and inflammation in the brain, improved motor function, and slowed disease progression, with a strong safety profile.
Philip Kremer, MD, PhD, Research Director Neurology, Centre for Human Drug Research (CHDR), and principal investigator for this study, said current therapies are limited primarily to symptom management, so there remains a persistent and urgent need for novel approaches to meaningfully address the disease and slow progression. Kremer added that as the healthcare community comes to understand the causative connection between peripheral triggers and neurodegenerative diseases, the insights from this trial will help further refine a strong clinical development program to demonstrate how this selective small molecule can alter the trajectory of Parkinson’s disease.
Vertero Therapeutics is a clinical-stage company pioneering science beyond the brain to treat neurodegenerative diseases at their source. Vertero’s development pipeline of differentiated therapies targets the peripheral nervous system to delay onset and slow progression of challenging conditions such as Parkinson’s disease. The company also has an asset targeting bile acid dysregulation in early development for undisclosed indications.
For more information on VT-5006, please visit Vertero’s Science page.
Geoffrey Mogilner, Mogilner Solutions, LLC
geoff@mogilner.com
Source: Vertero Therapeutics
